Apellis Pharmaceuticals, Inc. (APLS)
NASDAQ: APLS · Real-Time Price · USD
17.43
-0.97 (-5.27%)
At close: Jun 27, 2025, 4:00 PM
17.43
0.00 (0.00%)
After-hours: Jun 27, 2025, 5:52 PM EDT
Apellis Pharmaceuticals Revenue
Apellis Pharmaceuticals had revenue of $166.80M in the quarter ending March 31, 2025, a decrease of -3.21%. This brings the company's revenue in the last twelve months to $775.84M, up 48.04% year-over-year. In the year 2024, Apellis Pharmaceuticals had annual revenue of $781.37M with 97.02% growth.
Revenue (ttm)
$775.84M
Revenue Growth
+48.04%
P/S Ratio
2.80
Revenue / Employee
$1,092,731
Employees
710
Market Cap
2.19B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 781.37M | 384.78M | 97.02% |
Dec 31, 2023 | 396.59M | 321.17M | 425.83% |
Dec 31, 2022 | 75.42M | 8.86M | 13.31% |
Dec 31, 2021 | 66.56M | -184.08M | -73.44% |
Dec 31, 2020 | 250.65M | - | - |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
APLS News
- 21 days ago - Apellis and Sobi Announce EMPAVELI® (pegcetacoplan) Showed Sustained Efficacy at One Year in Phase 3 Study for C3G and Primary IC-MPGN - GlobeNewsWire
- 23 days ago - Apellis Pharmaceuticals to Present at the Goldman Sachs 46th Annual Global Healthcare Conference - GlobeNewsWire
- 5 weeks ago - Apellis Pharmaceuticals: Have Some Patience - Seeking Alpha
- 7 weeks ago - Apellis Pharmaceuticals, Inc. (APLS) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - Apellis Pharmaceuticals Reports First Quarter 2025 Financial Results - GlobeNewsWire
- 7 weeks ago - Apellis Pharmaceuticals to Present at Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Apellis Pharmaceuticals to Host Conference Call on May 7, 2025, to Discuss First Quarter 2025 Financial Results - GlobeNewsWire
- 2 months ago - Apellis Announces Craig Wheeler to Join the Board of Directors - GlobeNewsWire